Abstracts with Phase II data for several non-alcoholic steatohepatitis therapies were published ahead of next month's American Association for the Study of Liver Diseases meeting in San Francisco.
Among them, Gilead Sciences Inc. (NASDAQ:GILD) reported new data for GS-9674, its non-steroidal agonist of farnesoid X receptor (FXR; NR1H4).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,